Share This Article:

Thirty years of scientific research on second-generation antipsychotic drugs in Japan: A bibliometric analysis

Abstract Full-Text HTML XML Download Download as PDF (Size:709KB) PP. 18-25
DOI: 10.4236/ojpsych.2013.31004    3,678 Downloads   5,700 Views   Citations

ABSTRACT

Aims:Research on second-generation antipsychotic drugs (SGAs) has experienced great development in last decades.We did a bibliometric study on the scientific publications on SGAs in Japan.Methods: With theEMBASEandMEDLINEdatabases, we chose papers published from Japan with SGA descriptors. Price’s law and Bradford’s law has been used as bibliometric indicators for quantitating production and dispersion, respectively, of published papers on SGAs. We also calculated the participation index of different countries, and correlated those bibliometric data with some social and health data from Japan (such as totalper capitaexpenditure on health and gross domestic expenditure on research and development). Results: A sum of 669 original documents were published from Japan from 1982 to 2011. Those results fulfilled Price’s law, with scientific production on SGAs showing exponential growth (correlation coefficientr= 0.9261, as against anr= 0.8709 after linear adjustment). The most studied SGAs in Japan wererisperidone (n= 192), aripiprazole (n= 109), and olanzapine (n= 106). Division of documents into Bradford zones yielded a nucleus occupied exclusively by theProgress in Neuro-Psychopharmacology and Biological Psychiatry(49 articles). Those publications were in 157 different journals. Seven of the first 10 frequently used journals had an impact factor of being greater than 3. Conclusions: The SGA publications in Japan have been through exponential growth over the studied period, without evidence of reaching a saturation point.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

López-Muñoz, F. , Shinfuku, N. , Shen, W. , Moreno, R. , Molina, J. , Rubio, G. , Huelves, L. , Noriega, C. , Pérez-Nieto, M. and Álamo, C. (2013) Thirty years of scientific research on second-generation antipsychotic drugs in Japan: A bibliometric analysis. Open Journal of Psychiatry, 3, 18-25. doi: 10.4236/ojpsych.2013.31004.

References

[1] López-Munoz, F., Alamo, C., Cuenca, E., Shen, W.W., Clervoy, P. and Rubio, G. (2005) History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry, 17, 113-135. doi:10.1080/10401230591002002
[2] Shen, W.W. (1999) A history of antipsychotic drug development. Comprehensive Psychiatry, 40, 407-414. doi:10.1016/S0010-440X(99)90082-2
[3] Kane, J., Honigfeld, G., Singer, J. and Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 780-796.
[4] Hippius, H. (1999) A historical perspective of clozapine. Journal of Clinical Psychiatry, 60, 22-23.
[5] López-Munoz, F. and álamo, C. (2011) Neurobiological background for the development of new drugs in schizophrenia. Clinical Neuropharmacology, 34, 111-126. doi:10.1097/WNF.0b013e318215c2f7
[6] Shinfuku, N. (2012) What are happening in the mental health system in Japan: Some observations. Taiwanese Journal of Psychiatry, 26, 70-76.
[7] López-Munoz, F., Vieta, E., Rubio, G., García-García, P. and Alamo, C. (2006) Bipolar disorder as an emerging pathology in the scientific literature: A bibliometric approach. Journal of Affective Disorders, 92, 161-170. doi:10.1016/j.jad.2006.02.006
[8] López-Munoz, F., álamo, C., Quintero-Gutiérrez, F.J. and García-García, P. (2008) A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005. European Child and Adolescent Psychiatry, 17, 381-391. doi:10.1007/s00787-008-0680-1
[9] López-Munoz, F., García-García, P., Sáiz-Ruiz, J., Mezzich, J.E., Rubio, G., Vieta, E. and álamo, C. (2008) A bibliometric study of the use of the classification and diagnostic systems in psychiatry over the last 25 years. Psychopathology, 41, 214-225. doi:10.1159/000125555
[10] López-Munoz, F., Alamo, C., Rubio, G., García-García, P., Martín-Agueda, B. and Cuenca, E. (2003) Bibliometric analysis of biomedical publications on SSRIs during the period 1980-2000. Depression & Anxiety, 18, 95-103. doi:10.1002/da.10121
[11] López-Munoz, F., Shen, W.W., Moreno, R., Molina, J.D., Noriega, C., Pérez-Nieto, M.A., Rubio, G. and álamo, C. (2012) International scientific productivity on secondgeneration antipsychotic drugs in Taiwan: A bibliometric study. Taiwanese Journal of Psychiatry, 26, 114-129.
[12] Price, D.J.S. (1963) Little science, big science. Columbia University Press, New York.
[13] Bradford, S.C. (1948) Documentation. Crosby Lockwood, London.
[14] OECD Health Division (2011) OECD Health Data 2011 —Frequently Requested Data. OECD, Paris.
[15] World Health Organisation Department of Health Statistics and Informatics (2011) World Health Statistics 2011. WHO, Geneva.
[16] Shen, W.W. (2011) Clinical Psychopharmacology for the 21 Century, the Third Edition (in Mandarin). Ho-Chi Publishing Company, Taipei.
[17] Clement, S., Singh, S., and Burns, T. (2003) Status of bipolar disorder research. British Journal of Psychiatry, 182, 148-152. doi:10.1192/bjp.182.2.148
[18] Theander, S.S. and Wetterberg, L. (2010) Schizophrenia in Medline 1950-2006: A bibliometric investigation. Schizophrenia Research, 118, 279-284. doi:10.1016/j.schres.2009.05.013
[19] Shen, W.W., López-Munoz, F. and Alamo, C. (2006) Acido valproico y carbamazepina en el tratamiento del trastorno bipolar: Desarrollo histórico. In: López-Munoz, F. and álamo, C., Eds., Historia de la Psicofarmacología, Médica Panamericana, Madrid, 2, 771-782.
[20] Takezaki, H. and Hanaoka, M. (1971) The use of carbamazepine (Tegretol) in the controlod manic-depressive psychosis and other manic, depressive states. Seishin Igaku (Folia Psychiatry Neurology) (in Japanese), 13, 173-182.
[21] Hirai, Y., Yamanaka, Y., Kusama, M., Ishibashi, T., Sugiyama, Y. and Ono, S. (2012) Analysis of the success rates of new drug development in Japan and the lag behind the US. Health Policy, 104, 241-246. doi:10.1016/j.healthpol.2011.11.008
[22] Shimazawa, R. and Ikeda, M. (2011) Delays in neurological drug development in Japan. Internal Medicine, 50, 1565-1568. doi:10.2169/internalmedicine.50.5061
[23] Shimazawa, R., Kusumi, I. and Ikeda, M. (2012) Delays in psychiatric drug development in Japan. Journal of Clinical Pharmacy and Therapeutics, 37, 348-351. doi:10.1111/j.1365-2710.2011.01311.x
[24] Tajima, O. (2001) Mental health care in Japan: Recognition and treatment of depression and anxiety disorders. Journal of Clinical Psychiatry, 62, 44.
[25] Sim, K., Su, A., Fujii, S., Chong, M.Y., Ungvari, G.S., Si, T., Chung, E.K., Tsang, H.Y., Chan, Y. H., Heckers, S., Shinfuku, N. and Tan, C.H. (2004) Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58, 178-183. doi:10.1111/j.1365-2125.2004.02102.x
[26] Sim, K., Chuan, H., Fujii, S., Yang, S.I., Chong, M.Y., Ungvari, G.S., Si, T., He, Y.L., Chung, E.K., Chan, Y.H., Shinfuku, N., Kua, E.H., Tan, C.H. and Sartorius, N. (2009) High-dose antipsychotic use in schizophrenia: A comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. British Journal of Clinical Pharmacology, 67, 110-117. doi:10.1111/j.1365-2125.2008.03304.x

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.